Biological properties of herpes simplex virus 2 replication-defective mutant strains in a murine nasal infection model

Virology

Volumn 278, Issue 1, 2000, Pages 137-150

  Jones, Cheryl A ^a   Taylor, Travis J ^a   Knipe, David M ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; IMMUNITY; IMMUNIZATION; IN SITU HYBRIDIZATION; MOUSE; MUTANT; NONHUMAN; NOSE INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS LOAD; VIRUS REPLICATION;

ANIMALIA; DNA VIRUSES; HERPES; HUMAN HERPESVIRUS 2; MURINAE;

EID: 0034610247     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2000.0628     Document Type: Article

References (62)

1. Suppression of herpes simplex virus type 1 (HSV-1)-induced pneumonia in mice by inhibition of inducible nitric oxide synthase (iNOS, NOS2)
2. Neuropathology of herpes simplex virus encephalitis in a rat seizure model
3. Efficacy of recombinant glycoprotein D subunit vaccines on the development of primary, recurrent, and latent genital infections with herpes simplex virus type 2 in guinea pigs
4. DNA immunization against experimental genital herpes simplex virus infection
5. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease
6. Neonatal herpes simplex virus infection: Pathogenesis and treatment in the guinea pig
7. Detection and characterization of latent HSV RNA by in situ and Northern blot hybridization in guinea pigs
8. Herpes simplex virus type 2 establishes latency in the mouse footpad
9. Genital herpes simplex virus infections. Clinical manifestations, course, and complications
10. Genital herpes and public health. Addressing a global problem
11. Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice
12. Construction and characterization of a replication-defective herpes simplex virus 21CP8 mutant strain and its use in immunization studies in a guinea pig model of genital herpes
13. Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection
14. Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2
15. Exercise, alveolar macrophage function, and susceptibility to respiratory infection
16. One functional copy of the long terminal repeat gene specifying the immediate-early polypeptide IE 110 suffices for a productive infection of human foetal lung cells by herpes simplex virus
17. Acute and latent herpes simplex virus neurological disease in mice immunized with purified virus-specific glycoproteins gB or gD
18. Herpes simplex virus encephalitis in a mouse model - PCR evidence for CNS latency following acute infection
19. Passive immunotherapy for encephalitis caused by herpes simplex virus
20. Macrophages and microglia in HSV-1 infected mouse brain
21. Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted
22. Herpes simplex virus type 2 in the United States, 1976 to 1994
23. Genetic evidence for multiple nuclear functions of the herpes simplex virus ICP8 DNA-binding protein
24. A LAT-associated function reduces productive-cycle gene expression during acute infection of murine sensory neurons with herpes simplex virus type 1
25. The percentage of trigeminal ganglia neurons expressing herpes simplex virus type 1 latency associated transcript correlates to reactivation in the New Zealand rabbit model
26. Herpes simplex latency
27. Pathogenesis of herpes simplex virus in congenitally athymic mice. The relative roles of cell-mediated and humoral immunity
28. Quantitative polymerase chain reaction analysis of herpes simplex virus DNA in ganglia of mice infected with replication-incompetent mutants
29. Acyclovir treatment of disseminated herpes simplex virus type 2 infection in weanling mice. Alteration of mortality and pathogenesis
30. Protection against establishment of latent infections in mice immunized with a non-pathogenic herpes simplex virus mutant and reinfected with the pathogenic parental strain
31. Definition of a series of stages in the association of two herpesviral proteins with the cell nucleus
32. Evidence for a novel regulatory pathway for herpes simplex virus gene expression in trigeminal ganglion neurons
33. Quantification of transcripts from the ICP4 and thymidine kinase genes in mouse ganglia latently infected with herpes simplex virus
34. The quantity of latent viral DNA correlates with the relative rates at which herpes simplex virus types 1 and 2 cause recurrent genital herpes outbreaks
35. Correlation between herpes simplex virus type 1 rate of reactivation from latent infection and the number of infected neurons in trigeminal ganglia
36. Effect of age and route of inoculation on outcome of neonatal herpes simplex infection in guinea pigs
37. Immunity in the female genital tract after intravaginal vaccination of mice with an attenuated strain of herpes simplex virus type 2
38. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020? Construction and evaluation in rodents
39. Characterization of herpes simplex virus type 2 transcription during latent infection of mouse trigeminal ganglia
40. Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge
41. Immunization with replicationdefective mutants of herpes simplex virus type 1: Sites of immune intervention in pathogenesis of challenge virus infection
42. Mechanisms of immunization with a replication-defective mutant of herpes simplex virus 1
43. Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection
44. Complementary lethal invasion of the central nervous system by nonneuroinvasive herpes simplex virus types 1 and 2
45. High-dose ocular infection with a herpes simplex virus type 1 ICP34.5 deletion mutant produces no corneal disease or neurovirulence yet results in wild-type levels of spontaneous reactivation
46. Differences in neurovirulence among isolates of Herpes simplex virus types 1 and 2 in mice using four routes of infection
47. Peripheral replication and latency reactivation kinetics of the non-neurovirulent herpes simplex virus type 1 variant 1716
48. Introduction: Objectives of herpes simplex virus vaccines seen from a historical perspective
49. The influence of different modes of immunization on the experimental genital herpes simplex virus infection of mice
50. Persistence of herpes simplex virus (HSV) infection in ganglia and peripheral tissues of guinea pigs
51. Retention of herpes simplex virus DNA sequences in the nuclei of mouse footpad keratinocytes after recovery from primary infection
52. Role of antibody in primary and recurrent herpes simplex virus infection
53. Characterization of herpes simplex virus 2 temperature-sensitive mutants whose lesions map in or near the coding sequences for the major DNA-binding protein
54. Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs
55. Genital reinfection after recovery from initial genital infection with herpes simplex virus type 2 in guinea pigs
56. Prospects for control of herpes simplex virus disease through immunization
57. Thymidine kinase deficient herpes simplex virus type 2 genital infection in guinea pigs
58. A thymidine kinase deficient HSV-2 strain causes acute keratitis and establishes trigeminal ganglionic latency, but poorly reactivates in vivo
59. Molecular analysis of a neuro-virulent herpes simplex virus type 2 strain with reduced thymidine kinase activity
60. Vaccine potential of a live avirulent herpes simplex virus
61. Correlation of virus replication, cytokine (TNF-alpha and IL-1) producing cells, neuronal necrosis and inflammation after intranasal infection of mice with herpes simplex virus strains of different virulence
62. Effect of immunization on acute and latent infections of vaginouterine tissue with herpes simplex virus types 1 and 2